Because of its proximal role in BCR signaling in CLL cells, the effects of Lck inhibition should be similar to idelalisib and ibrutinib and reduce lymphadenopathy and promote lymphocytosis. The gene discussed is LCK; the disease is B-cell chronic lymphocytic leukemia.